SUTRO BIOPHARMA INC (STRO) — insider trading
Health Care · NASDAQ
SUTRO BIOPHARMA INC (STRO) has 29 reported SEC Form 4 insider transactions in our data (latest 2026-09-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Gerber Hans-Peter | Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-09-18 | Gerber Hans-Peter | Officer (CHIEF SCIENTIFIC OFFICER) | Shares withheld for taxes / exercise cost | 1,345 | $15.34 | $20.6K | Form 4 |
| 2026-09-18 | Gerber Hans-Peter | Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-06-05 | MATSUI CONNIE | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Dybbs Michael | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Hunter Heidi | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Jagpal Sukhi | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Lobacki Joseph M | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | PANEK JAMES P | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Petree Daniel H | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-05 | Wigginton Jon Marc | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-02 | Chow Gregory K. | Officer (CFO) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-06-02 | Chow Gregory K. | Officer (CFO) | Option exercise / conversion | 2,500 | — | $0 | Form 4 |
| 2026-03-04 | Chung Jane | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 788 | — | $0 | Form 4 |
| 2026-03-04 | Chung Jane | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 282 | $21.31 | $6.0K | Form 4 |
| 2026-03-04 | Chung Jane | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 788 | — | $0 | Form 4 |
| 2026-03-04 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion (derivative) | 675 | — | $0 | Form 4 |
| 2026-03-04 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Shares withheld for taxes / exercise cost | 277 | $21.31 | $5.9K | Form 4 |
| 2026-03-04 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion | 675 | — | $0 | Form 4 |
| 2026-03-02 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Grant / award / vesting (derivative) | 33,600 | — | $0 | Form 4 |
| 2026-03-02 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Grant / award / vesting (derivative) | 4,200 | — | $0 | Form 4 |
| 2026-03-02 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion (derivative) | 2,356 | — | $0 | Form 4 |
| 2026-03-02 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Shares withheld for taxes / exercise cost | 970 | $20.55 | $19.9K | Form 4 |
| 2026-03-02 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion | 2,356 | — | $0 | Form 4 |
| 2026-03-01 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion (derivative) | 842 | — | $0 | Form 4 |
| 2026-03-01 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion (derivative) | 500 | — | $0 | Form 4 |
| 2026-03-01 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Shares withheld for taxes / exercise cost | 551 | $20.47 | $11.3K | Form 4 |
| 2026-03-01 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion | 842 | — | $0 | Form 4 |
| 2026-03-01 | Pauling David | Officer (Chief Admin. Ofcr. & GC) | Option exercise / conversion | 500 | — | $0 | Form 4 |
Ask the chat about STRO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SUTRO BIOPHARMA INC (STRO).
Last updated 2026-09-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.